Indication
Treatment of moderate to severe tardive dyskinesia in adults.
Official EMA Resources
View on EMA (ema.europa.eu)AI Drug & Interaction Analysis
Loading your page…
Loading your page…
Tardive Dyskinesia
Marketing Authorisation Holder: Teva GmbH
EMA Authorisation: 08/01/2026
INN: deutetrabenazine
AI Drug & Interaction Analysis
Free account required
Ask Osler about Austedo: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.